Bringing a new therapy from the lab bench to the patient’s bedside remains one of the most complex, expensive, and time-consuming journeys in modern science. It typically takes 10–15 years and over a billion dollars to get a molecule from discovery to regulatory approval, with many candidates failing to reach this stage. However, sponsors can significantly shorten timelines, lower costs, and enhance clinical success by implementing an efficient and well-integrated development strategy from the outset.
This blog outlines the stages of the preclinical-to-clinical journey, highlights common pitfalls that can delay programs, and discusses how a strategic framework, such as the one provided by CurexBio, can assist sponsors in accelerating their processes without compromising quality.
The transition from preclinical research to clinical development is considered a challenging phase in drug development. It requires the conversion of promising laboratory data into a solid, regulator-compliant argument for human testing. This stage often encounters obstacles due to several common factors.
- Fragmented data packages lack clear connections among mechanism, safety, and dosing rationale.
- Late engagement with regulators results in unnecessary protocol amendments.
- Identifying manufacturing and formulation gaps only during IND-enabling studies can lead to significant challenges in the drug development process.
- Misaligned timelines among toxicology, CMC, and clinical operations teams can lead to inefficiencies and delays in projects.
Addressing these gaps necessitates a unified approach that integrates preclinical and clinical research into a seamless pipeline.
- Target Validation and Early Translational Planning
Efficient programs start by defining objectives upfront. Establishing strong translational biomarkers and a clear hypothesis about the mechanism of action before committing resources ensures that preclinical endpoints align with measurable clinical trial outcomes, helping to avoid costly revisions later when addressing regulatory or investigative queries about the predictive value of preclinical results for clinical benefits.
- IND-Enabling Studies
GLP toxicology, pharmacokinetics, and safety pharmacology studies are essential regulatory requirements. However, the most effective programs leverage these studies to provide strategic insights, aiding in first-in-human dose selection, identifying at-risk populations, and anticipating safety monitoring needs. Viewing these studies merely as a compliance task often leads to significant delays.
- CMC and Manufacturing Readiness
Chemistry, Manufacturing, and Controls (CMC) often act as a hidden bottleneck in drug development, where scaling processes, ensuring stable formulations, and establishing a supply chain for clinical trial materials are time-consuming. Initiating CMC work alongside late-stage preclinical studies is a highly strategic move for sponsors, as it can mitigate delays in the development timeline.
- Proactive Regulatory Strategy
Engaging regulatory agencies early helps sponsors validate their development plans, allowing for informed decisions before committing to costly studies. A proactive regulatory strategy addresses potential questions regarding study design, patient population, and endpoints ahead of submission.
- Integrated Clinical Trial Design
Efficient clinical development begins with a comprehensive plan that integrates all phases, from Phase 1 to Phase 3 and beyond. Utilizing adaptive trial designs, seamless Phase 1/2 studies, and biomarker-driven patient selection can accelerate progress toward pivotal readouts while ensuring statistical validity and patient safety.
Common Pitfalls That Undermine Efficiency
- Treating preclinical and clinical teams as separate silos leads to limited data handoff, affecting collaboration and efficiency in the research process.
- Underestimating the lead time needed for GMP manufacturing scale-up
- Delaying biostatistics and regulatory input until protocols are nearly final
- Failing to build contingency plans for negative or ambiguous preclinical signals
- Choosing CROs or partners based on cost alone rather than track record and strategic fit
A comprehensive understanding of the entire development pathway is essential to avoid common pitfalls, which poses a challenge for many sponsors, especially smaller biotechnology companies.
This is the gap CurexBio aims to address by integrating preclinical and clinical development through a coordinated pathway that includes translational science, IND-enabling studies, CMC planning, regulatory strategy, and clinical trial design.
For sponsors, this means:
- Earlier risk identification emphasizes clinical relevance alongside regulatory compliance.
- Timelines are streamlined by planning CMC, toxicology, and clinical operations concurrently.
- Data packaging anticipates regulatory inquiries, facilitating smoother communication with agencies.
- Collaboration is enhanced by engaging a single strategic partner, minimizing the need for multiple vendors.
By fostering coordination in drug development from preclinical stages to clinical execution, CurexBio enables sponsors to evade the fragmented, reactive approaches that can delay progress and increase costs.
The transition from preclinical studies to clinical development can be streamlined with a comprehensive strategy that incorporates translational science, regulatory foresight, manufacturing readiness, and clinical design from the outset. CurexBio offers an integrated approach and clinical development services that transforms the traditionally fragmented and high-risk process into an efficient, coordinated strategy, thereby de-risking programs and expediting patient access.
